ACE-031

ACE-031 (also known as Ramatercept, CAS: 1621169-52-5, Myostatin Inhibitory Peptide 7) is a recombinant ActRIIB-Fc fusion protein and potent myostatin/activin ligand trap developed by Acceleron Pharma (now a subsidiary of Merck). It was designed to treat muscle-wasting disorders but was discontinued due to safety issues.

1mg*10vials

$50

Product Information

Mechanism of Action (Detailed)

Primary Targets

Myostatin (GDF-8): Major negative regulator of muscle growth
GDF-11: Related to aging, muscle, and bone homeostasis
Activin A/B: Inhibits muscle and promotes fat accumulation

Pathway Inhibition

ACE-031 binds ligands in blood/extracellular space
Prevents ligands from binding native ActRIIB on muscle/bone cells
Blocks SMAD2/3 signaling (the inhibitory pathway that suppresses protein synthesis and satellite cell activation)
Net effect: Uninhibited muscle growth, increased bone density, reduced fat

Off-Target Binding

Binds BMP-9/10 (critical for vascular integrity and endothelial function)
Causes bleeding, telangiectasias, and vascular fragility

Physiological Effects & Therapeutic Potential

Muscle

Dose-dependent lean body mass (LBM) gain (up to 3.3% in healthy humans)
Increased muscle fiber size and satellite cell proliferation
Reduced muscle atrophy (disuse, age-related, disease-related)

Bone

Increased bone mineral density (BMD)
Reduced osteoclast activity (bone resorption)

Metabolism

Decreased fat mass
Improved insulin sensitivity

Anti-Aging Relevance

Anti-sarcopenia: Counters age-related muscle loss and weakness
Physical function: Improves strength, mobility, exercise capacity
Bone protection: Mitigates osteoporosis in aging